Watkins C - Search Results

1

Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes.

Paganoni S, Watkins C, Cawson M, Hendrix S, Dickson SP, Knowlton N, Timmons J, Manuel M, Cudkowicz M. Paganoni S, et al. Among authors: watkins c. Muscle Nerve. 2022 Aug;66(2):136-141. doi: 10.1002/mus.27569. Epub 2022 May 31. Muscle Nerve. 2022. PMID: 35508892 Free PMC article. Clinical Trial.

2

A simple method for combining binomial counts or proportions with hazard ratios for evidence synthesis of time-to-event data.

Watkins C, Bennett I. Watkins C, et al. Res Synth Methods. 2018 Sep;9(3):352-360. doi: 10.1002/jrsm.1301. Epub 2018 May 31. Res Synth Methods. 2018. PMID: 29707913

3

Letter to the Editor: comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.

Parekh K, Watkins C. Parekh K, et al. Among authors: watkins c. J Comp Eff Res. 2021 Dec;10(17):1265-1266. doi: 10.2217/cer-2021-0123. Epub 2021 Oct 5. J Comp Eff Res. 2021. PMID: 34608807 Free article. No abstract available.

4

Adjusting overall survival for treatment switches: commonly used methods and practical application.

Watkins C, Huang X, Latimer N, Tang Y, Wright EJ. Watkins C, et al. Pharm Stat. 2013 Nov-Dec;12(6):348-57. doi: 10.1002/pst.1602. Epub 2013 Oct 18. Pharm Stat. 2013. PMID: 24136868

5

Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.

Schulz C, Gandara D, Berardo CG, Rosenthal R, Foo J, Morel C, Ballinger M, Watkins C, Chu P. Schulz C, et al. Among authors: watkins c. Clin Lung Cancer. 2019 Nov;20(6):451-460.e5. doi: 10.1016/j.cllc.2019.06.017. Epub 2019 Jun 19. Clin Lung Cancer. 2019. PMID: 31375454

6

Decision-making in early clinical drug development.

Frewer P, Mitchell P, Watkins C, Matcham J. Frewer P, et al. Among authors: watkins c. Pharm Stat. 2016 May;15(3):255-63. doi: 10.1002/pst.1746. Epub 2016 Mar 17. Pharm Stat. 2016. PMID: 26991401

7

Utility values in health technology assessments: a statistician's perspective.

Whately-Smith C, Watkins C, Mann H, Fletcher C, Ducournau P. Whately-Smith C, et al. Among authors: watkins c. Pharm Stat. 2014 May-Jun;13(3):184-95. doi: 10.1002/pst.1616. Epub 2014 Apr 2. Pharm Stat. 2014. PMID: 24692364

8

A Randomized Study of Electronic Diary versus Paper and Pencil Collection of Patient-Reported Outcomes in Patients with Non-Small Cell Lung Cancer.

Ring AE, Cheong KA, Watkins CL, Meddis D, Cella D, Harper PG. Ring AE, et al. Patient. 2008 Apr 1;1(2):105-13. doi: 10.2165/01312067-200801020-00006. Patient. 2008. PMID: 22272807

9

Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.

Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums DV, Speake G, Holloway B, Bunn PA Jr, Franklin WA. Hirsch FR, et al. Among authors: watkins c. Cancer. 2008 Mar 1;112(5):1114-21. doi: 10.1002/cncr.23282. Cancer. 2008. PMID: 18219661 Free PMC article. Clinical Trial.

10

Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.

Chang A, Parikh P, Thongprasert S, Tan EH, Perng RP, Ganzon D, Yang CH, Tsao CJ, Watkins C, Botwood N, Thatcher N. Chang A, et al. Among authors: watkins c. J Thorac Oncol. 2006 Oct;1(8):847-55. J Thorac Oncol. 2006. PMID: 17409969 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

869 results

Search Page

Filters